- |||||||||| Trial completion date, Trial primary completion date: Safety and Efficacy of APG-157 in Head and Neck Cancer (clinicaltrials.gov) - Aug 2, 2023
P2, N=24, Recruiting,
Not yet recruiting --> Recruiting Trial completion date: Apr 2023 --> Jul 2024 | Trial primary completion date: Apr 2023 --> Jul 2024
- |||||||||| APG-157 / Aveta Biomics
Biomarker, Journal: Cell-Free RNA as a Novel Biomarker for Response to Therapy in Head & Neck Cancer. (Pubmed Central) - May 24, 2022
A platelet-related transcriptional signature could be detected in cancer patients but not in healthy individuals, indicating a platelet-centric pathway involved in the development of HNC. These results from a Phase 1 study are a proof of principle of the utility of cfRNAs as non-invasive circulating biomarkers for monitoring the efficacy of APG-157 in HNC.
- |||||||||| APG-157 / Aveta Biomics
Enhanced tumor control with a combination of APG-157 and immune checkpoint inhibitors for head and neck cancer. (Available On Demand; 306) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1711;
These results from a Phase 1 study are a proof of principle of the utility of cfRNAs as non-invasive circulating biomarkers for monitoring the efficacy of APG-157 in HNC. These study results indicate that APG-157 is able to modulate the immune system and fecal microbial species that could potentially lead to improved anti-tumor immunity and warrants further studies to define mechanism and the potential for human clinical trial.
- |||||||||| Enrollment open: Safety and Efficacy of APG-157 in Head and Neck Cancer (clinicaltrials.gov) - Apr 25, 2022
P2, N=24, Recruiting,
These study results indicate that APG-157 is able to modulate the immune system and fecal microbial species that could potentially lead to improved anti-tumor immunity and warrants further studies to define mechanism and the potential for human clinical trial. Not yet recruiting --> Recruiting
|
